60
Participants
Start Date
November 30, 2004
Primary Completion Date
February 28, 2007
Study Completion Date
February 28, 2007
IMC-11F8
"Cohort 1~100 mg I.V."
IMC-11F8
"Cohort 2~200 mg I.V."
IMC-11F8
"Cohort 3~400 mg I.V."
IMC-11F8 I.V.
"Cohort 4~600 mg I.V."
IMC-11F8
"Cohort 5~800 mg I.V."
IMC-11F8
"Cohort 6~1000 mg I.V."
IMC-11F8
"Cohort 1~100 mg I.V."
IMC-11F8
"Cohort 2~200 mg I.V."
IMC-11F8
"Cohort 3~400 mg I.V."
IMC-11F8
"Cohort 4~600 mg I.V."
IMC-11F8
"Cohort 5~800 mg I.V."
IMC-11F8
"Cohort 6~1000 mg I.V."
ImClone Investigational Site, Amsterdam
ImClone Investigational Site, Utrecht
Eli Lilly and Company
INDUSTRY